Pharma Partnering US: $66B Deal Surge, Lilly & Sun Lead
Pharma dealmaking has surged to $66 billion as the Pharma Partnering Summit US 2026 gets underway. Sun Pharma is acquiring Organon for $11.75 billion, and Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion.
Key Takeaways
- Pharma Partnering Summit US 2026 is underway in San Diego, bringing together business development leaders.
- Pharma dealmaking has surged to $66 billion in valuation, doubling the previous year's figures.
- Sun Pharmaceuticals is set to acquire Organon for $11.75 billion, expanding its presence in women's health.
- Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, marking its sixth acquisition this year.
The Pharma Partnering Summit US 2026 is being held in San Diego, California, from April 29–30, 2026, gathering senior business development and licensing executives. This year's summit takes place amidst a significant surge in pharmaceutical dealmaking activity, with the total valuation of deals approximately doubling compared to the previous year.
The Pharma Partnering Summit US event provides a venue for companies to explore collaborations and acquisitions. This year's event is particularly noteworthy given the increased level of investment and strategic realignment occurring within the pharmaceutical industry.
Pharma Dealmaking Surge
Pharma dealmaking has reached approximately $66 billion in valuation in 2026, a substantial increase from the previous year. This surge reflects a period of intense investment and strategic repositioning as companies seek to bolster their pipelines and market presence.
Major Acquisitions
Several major acquisitions have been announced recently, highlighting the industry's appetite for growth through strategic combinations:
- Sun Pharmaceuticals is acquiring Organon (brand name not applicable) for $11.75 billion, a move that will significantly enhance its portfolio in women's health.
- Eli Lilly is acquiring Ajax Therapeutics (brand name not applicable) for up to $2.3 billion. This acquisition marks Lilly's sixth of the year, underscoring its aggressive growth strategy.
- Earlier in April, Merck finalized its $6.7 billion acquisition of Terns Pharma (brand name not applicable) and its $9.2 billion acquisition of Cidara Therapeutics (brand name not applicable).
Key Partnership Announcements (Q1 2026)
In addition to acquisitions, several key partnerships have been announced in the first quarter of 2026:
- OPKO Health & Entera Bio: Expanded their collaboration on an oral long-acting PTH (parathyroid hormone variant) tablet for hypoparathyroidism. The collaboration features 50/50 ownership and cost-sharing, with an IND filing planned for late 2026 following positive PK/PD data from December 2025.
- Santhera Pharmaceuticals & Nxera Pharma: Entered into an exclusive license agreement in January 2026 for AGAMREE (vamorolone) in Japan/APAC, valued at up to $215 million plus royalties, including $40 million upfront ($30 million cash + $10 million equity).
- Santhera & Catalyst Pharmaceuticals: The AGAMREE (vamorolone) North America partnership generated $117 million in US sales in 2025, resulting in a $12.5 million milestone payment to Santhera. The 2026 sales guidance is projected at $140-150 million.
Market & Investor Implications
The surge in pharma dealmaking and strategic partnerships reflects a dynamic market environment. Investors are closely watching these developments, as they can significantly impact company valuations and future growth prospects. Regulatory developments also continue to play a crucial role in shaping industry strategy.
What to Watch Next
The industry will be closely monitoring the integration of acquired companies and the progress of partnered programs. Upcoming data readouts and regulatory decisions will also be key catalysts for market activity.
Frequently Asked Questions
-
What is the Pharma Partnering Summit US?
The Pharma Partnering Summit US is an annual event that brings together senior business development and licensing leaders in the pharmaceutical industry to facilitate dealmaking and strategic collaborations.
-
Why is there a surge in pharma dealmaking?
The surge in pharma dealmaking reflects a strategic realignment within the industry, driven by the need to bolster pipelines, expand market presence, and capitalize on emerging therapeutic areas.
-
What are some of the key acquisitions announced recently?
Key acquisitions include Sun Pharmaceuticals acquiring Organon for $11.75 billion and Eli Lilly acquiring Ajax Therapeutics for up to $2.3 billion. Merck also completed its acquisitions of Terns Pharma and Cidara Therapeutics earlier in April.
-
What is AGAMREE (vamorolone)?
AGAMREE (vamorolone) is a drug commercialized by Santhera and Catalyst Pharmaceuticals through a North American partnership that generated $117 million in sales in 2025.
